Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01844726 · ClinicalTrials.gov registry record · Phase 2
Effects of GLYX-13 on Learning and Memory in Healthy Individuals and Those With Psychiatric Illness
A Phase 2 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT01844726 is a Phase 2 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 44 participants.
The verdict
NCT01844726, a Phase 2 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
The present study proposes to evaluate the potential cognitive enhancing effects of GLYX-13, an NMDAR partial agonist, among a group of healthy adults and those with psychiatric illness on a series of functional magnetic resonance imaging (fMRI) learning and memory tasks.
Interventions
- DRUG Placebo
- DRUG GLYX-13
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2013-05 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01844726
The ClinicalTrials.gov registry entry for NCT01844726 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01844726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01844726 about?
NCT01844726 is a clinical study titled "Effects of GLYX-13 on Learning and Memory in Healthy Individuals and Those With Psychiatric Illness". The present study proposes to evaluate the potential cognitive enhancing effects of GLYX-13, an NMDAR partial agonist, among a group of healthy adults and those with psychiatric illness on a series of functional magnetic resonance imaging (fMRI) learning and memory tasks.
What is the current status of trial NCT01844726?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2013-05. Estimated completion is 2016-01.
What interventions are being tested in trial NCT01844726?
The interventions under investigation include: Placebo (DRUG), GLYX-13 (DRUG).
Who is sponsoring clinical trial NCT01844726?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.